Natalia Perekhvatova

CEO

Built Mitotech's mitochondrial pipeline from early science to clinical validation and commercial partnership. Structured $40M out-licensing deal with Essex Biotechnology. Prior: Citigroup, Amadeus. MBA, INSEAD.

John M. Barberich

CFO

Decades of biotech finance experience. Co-founder and CFO of ACADIA Pharmaceuticals (NASDAQ: ACAD). CFO, Omrix Biopharmaceuticals (acquired by J&J). CFO, Scriptgen (acquired by Roche). Acting CBO/CFO of Lumos Pharma (NASDAQ: LUMO). Venture Partner, Nordic Biotech.

Dr. Stanislava Macura

Clinical Lead (Advisor)

Experienced clinical development physician, Phase I–II metabolic and obesity studies, including prior clinical development roles at Novo Nordisk (cardiometabolic). Ex-Medical Director for CagriSema development. Prior: Zealand Pharma, Novo Nordisk. MD, University of Novi Sad.

Dr. Maxim Skulachev

Chief Scientific Officer

Thought leader in mitochondrial research. Leads core MoA research, formulation and preclinical efficacy. Heads new lead compound discovery. Prior: Mitolab (Israel), Icon Genetics (Germany). PhD, Molecular Biology.

Dr. Anton Petrov

Chief Operating Officer

Expert in drug development operations across US and EU. Leads study design and data interpretation. 20+ years in biotechnology operations and data analytics. Prior: BioDiscovery, Infoquant. PhD in statistics, University of Southern California; MBA, INSEAD.

Dr. Alex Schwarz

Manufacturing Lead (Advisor)

Seasoned drug development expert with deep CMC and regulatory expertise. Led API and drug manufacturing at Novartis, Baxter and Braeburn. PhD, University of Bonn.